The FDA must remove an unnecessary barrier to the use of clozapine for treatment-resistant schizophrenia The Clozapine Risk Evaluation and Mitigation Strategy is hurting, not helping, patients

https://www.statnews.com/2025/02/13/clozapine-rems-fda-advisory-panel-neutropenia-treatment-resistant-schizophrenia/